Skip to content

US · ANVS · BIOTECHNOLOGY

Annovis Bio, Inc. (ANVS) intrinsic value and stock valuation

$0.71as of 2026-11-21 · Mkt cap 36.79M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Annovis Bio, Inc. DCF and intrinsic value

InvestorsCraft values ANVS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANVS’s statements →

Annovis Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Malvern, PA 19355 annovisbio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-28.85M
20172025
Free cash flow
-$-25.62B
20172025
Total equity
$16.9M+17.4% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-29.7M-$-26.69M-$-45.03M-$-25.51M-$-14.54M
Net income-$-28.85M-$-24.59M-$-56.2M-$-25.33M-$-14.49M
EPSd-$-1.4M-$-2.01M-$-6.23M-$-3.1M-$-1.9M
Operating cash flow-$-25.62B-$-21.89B-$-39.97M-$-17.31M-$-9.13M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-25.62B-$-21.89B-$-39.97M-$-17.31M-$-9.13M
Total assets$21.1M$13.9M$10.2M$36M$46M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-19.53M-$-10.55M-$-5.75M-$-28.38M-$-45.69M
Total equity$16.9M$9.31M-$-7.75M$28.3M$44.5M
Cash and short-term investments$19.5M$10.6M$5.75M$28.4M$45.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$25.2M$20M$38.8M$16.5M$8.48M
Selling, general and administrative expenses$4.48M$6.7M$6.24M$9M$6.06M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$29.7M$26.7M$45M$25.5M$14.5M
Cost and expenses$29.7M$26.7M$45M$25.5M$14.5M
Interest income$700K$330K$670K$180K$10K
Interest expense$0.00$1.85M$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Ebitda-$-28.85M-$-22.74M-$-56.2M-$-25.33M-$-14.5M
Operating income-$-29.7M-$-26.69M-$-45.03M-$-25.51M-$-14.54M
Total other income/expenses, net$840K$2.1M-$-11.17M$180K$50K
Income before tax-$-28.85M-$-24.59M-$-56.2M-$-25.33M-$-14.49M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-28.85M-$-24.59M-$-56.2M-$-25.33M-$-14.49M
Weighted average shares outstanding$20.6M$12.2M$9.02M$8.16M$7.63M
Weighted average diluted shares outstanding$20.6M$12.2M$9.02M$8.16M$7.63M
Balance sheet
20252024202320222021
Cash and short-term investments$19.5M$10.6M$5.75M$28.4M$45.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$21.1M$13.9M$10.2M$36M$46M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$0.00
Total assets$21.1M$13.9M$10.2M$36M$46M
Accounts payable$2.59M$2.31M$1.29M$3.96M$690K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.64M$3.88M$4.28M$7.7M$1.51M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$590K$740K$13.7M$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$4.23M$4.62M$18M$7.7M$1.51M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-163.7M-$-134.85M-$-110.26M-$-54.05M-$-28.73M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$16.9M$9.31M-$-7.75M$28.3M$44.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-19.53M-$-10.55M-$-5.75M-$-28.38M-$-45.69M
Cash flow statement
20252024202320222021
Net income-$-28.85B-$-24.59B-$-56.2M-$-25.33M-$-14.49M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.8B$3.84B$4.63M$9.15M$4.7M
Change in working capital$1.58M$680K-$-230K-$-1.14M$660K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$280K$1.01M-$-2.67M$3.27M$350K
Net cash provided by operating activities-$-25.62B-$-21.89B-$-39.97M-$-17.31M-$-9.13M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$34.6M$18.7M$16.9M$0.00$46.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$34.6B$26.7B$17.3M$0.00$46.7M
Net change in cash$8.98B$4.8B-$-22.62M-$-17.31M$37.6M
Cash at end of period$19.5B$10.6B$5.75M$28.4M$45.7M
Operating cash flow-$-25.62B-$-21.89B-$-39.97M-$-17.31M-$-9.13M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-25.62B-$-21.89B-$-39.97M-$-17.31M-$-9.13M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Annovis Bio, Inc.

        Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

        CEO
        Maria L. Maccecchini
        Employees
        8
        Beta
        1.19

        Explore

        Frequently asked questions

        What is the intrinsic value of Annovis Bio, Inc. (ANVS)?

        InvestorsCraft does not currently publish an intrinsic value for ANVS. How the IC value is calculated.

        Is ANVS undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANVS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.